Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Radiation Therapy in Treating Women With Localized Breast Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: April 5, 2005
Last updated: February 6, 2009
Last verified: May 2007

April 5, 2005
February 6, 2009
January 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00107497 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Radiation Therapy in Treating Women With Localized Breast Cancer
Prospective Randomised Clinical Trial Testing 5.7 Gy and 6.0 Gy Fractions of Whole Breast Radiotherapy in Terms of Late Normal Tissue Responses and Tumour Control - FAST

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy in different ways and giving it after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This randomized clinical trial is studying radiation therapy to see how well it works in treating women with localized breast cancer.


  • Compare late normal tissue effects of standard vs 2 different dose levels of hypofractionated adjuvant whole breast radiotherapy, in terms of changes in photographic breast appearance, in women with localized breast cancer who are at average or low risk of recurrence.
  • Compare tumor control in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are randomized to 1 of 3 treatment arms.

  • Arm I (control): Patients undergo standard radiotherapy 5 days a week for 5 weeks.
  • Arm II: Patients undergo hypofractional radiotherapy once a week for 5 weeks.
  • Arm III: Patients undergo hypofractional radiotherapy (at a lower dose than arm II) once a week for 5 weeks.

After completion of study treatment, patients are followed annually for 5-10 years.

PROJECTED ACCRUAL: A total of 900 patients (300 per treatment arm) will be accrued for this study within 12 months.

Not Provided
Allocation: Randomized
Primary Purpose: Treatment
Breast Cancer
  • Procedure: adjuvant therapy
  • Radiation: radiation therapy
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided


  • Diagnosis of invasive carcinoma of the breast

    • Localized disease

      • Pathological tumor size < 3.0 cm in diameter
      • Axillary node negative
  • At average or low risk of local tumor recurrence
  • Must have undergone prior breast-preserving surgery

    • No prior mastectomy
    • Complete microscopic resection of tumor
  • Hormone receptor status:

    • Not specified



  • 50 and over


  • Female

Menopausal status

  • Not specified

Performance status

  • Not specified

Life expectancy

  • Not specified


  • Not specified


  • Not specified


  • Not specified


  • Fertile patients must use effective contraception


Biologic therapy

  • Not specified


  • No prior neoadjuvant or adjuvant cytotoxic chemotherapy

Endocrine therapy

  • Not specified


  • No concurrent lymphatic radiotherapy
  • No concurrent radiotherapy boost to the breast


  • See Disease Characteristics
50 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
CDR0000417730, ICR-04/MRE06/17, ICR-FAST, ICR-FAST-04/MRE06/17, EU-20506
Not Provided
Not Provided
Not Provided
Not Provided
Institute of Cancer Research, United Kingdom
Not Provided
Study Chair: John R. Yarnold, MD, FRCR Royal Marsden NHS Foundation Trust
National Cancer Institute (NCI)
May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP